Article
The Clinical Tumor Lysis Syndrome in a Patient with Mixed Phenotype Acute Leukemia Undergoing Induction with Venetoclax and Azacitidine: A Case Report.
Chemotherapy - 1 Jan 2022
Drozd-Sokolowska Joanna, Mądry Krzysztof, Siewiorek Kinga, Feliksbrot-Bratosiewicz Magdalena, Stokłosa Tomasz, Gierej Beata, Stefaniak Agnieszka, Paszkowska-Kowalewska Małgorzata, Sokołowski Jacek, Sankowski Bartłomiej, Basak Grzegorz Władysław
Abstract excerpt
A combination of azacitidine and venetoclax (AZA-VEN) has been approved for the treatment of adult treatment-naïve acute myeloid leukemia (AML) patients, ineligible for intensive chemotherapy. The protocol may also constitute an alternative for the treatment of patients with mixed phenotype acute leukemia (MPAL), for which no established treatment guidelines exist. It may be anticipated, that alike in AML or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
